Warnings and Cautions The peptide may increase the risk of thyroid C-cell tumors, including medullary thyroid carcinoma, based on animal studies
However, the CMS BALANCE model and the Medicare GLP-1 Bridge program launching in July 2026 will begin providing limited coverage for eligible beneficiaries with specific comorbidities at a $50 monthly copay
There are multiple weight loss and diabetes medications that use either tirzepatide or semaglutide to treat type 2 diabetes or weight-related health conditions: Both Mounjaro and Zepbound are manufactured by Eli Lilly, while Wegovy and Ozempic are made by Novo Nordisk
Both may be contraindicated if you have: Personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2, history of severe pancreatitis, current pregnancy or plans to become pregnant, or severe kidney disease
Blood Sugar Control Studies have shown that Tirzepatide may be more effective than Semaglutide in lowering HbA1c levels (a key marker for long-term blood sugar control)